TABLE 2.
Summary of clinical trials of parmiparib in the treatment of ovarian cancer.
| Number | Combination agent | Population | N | Phase | Status | Primary outcome measures/results |
|---|---|---|---|---|---|---|
| NCT03333915 | NR | Chinese patients with advanced OC, fallopian cancer, and primary peritoneal cancer | 128 | I/II | Active, not recruiting | • Phase I: Number of participants with treatment-related adverse events |
| • Phase II: ORR | ||||||
| NCT02361723 | NR | PSOC with known or suspected harmful g/s BRCAm or HRD (+) | 101 | IA/I B | Completed | • ORR: CR + PR |
| • Primary PK 1/PK 2/PK 3 | ||||||
| NCT03519230 | NR | Chinese patients with PSOC | 216 | Ⅲ | Active, not recruiting | • PFS |
| NCT05489926 | NR | Patients with EOC who had previously been treated with a PARP inhibitor | 15 | Ⅱ | Recruiting | • CBR: CR + PR |
| NCT03933761 | NR | Patients with HGSOC or carcinosarcoma with fusion positive and reverse negative BRCA1/2 m | 0 | Ⅱ | Withdrawn | • CBR as assessed by RECIST v1.1 or by Gynecological Cancer Intergroup (GCIG) CA125 criteria |
| NCT05494580 | Surufatinib | PROC patients who have received PARP inhibitor treatment once | 38 | Ib/II | Not yet recruiting | • MTD (phase Ib) |
| • Determination of PR2D (phase Ib) | ||||||
| • ORR (phase II): CR + PR | ||||||
| NCT04985721 | Tislelizumab | Patients with BRCA1/2m or without BRCA1/2m but with other germline or somatic mutations in other HR genes | 60 | Ⅱ | Recruiting | • CBR: PR + CR |
| NCT05044871 | NR | Patients with PROC | 160 | Ⅱ | Not yet recruiting | • ORR: CR + PR |
This study is an open-label, multicenter, umbrella study aimed to evaluate the combined, biomarker-driven, targeted treatment efficiency of Pamiparib, Bevacizumab, Tislelizumab, and Nab-paclitaxel in patients with platinum-resistant recurrent ovarian cancer (PROC). NCT05044871 is the NCT number of this study. NR indicates no combination of drugs. Patients with PROC shows that this study recruit patients with platinum-resistant recurrent ovarian cancer (PROC). ORR: CR + PR is the main clinical evaluation index of this experiment. ORR, Objective response rate; CR, complete response; PR, partial response.